MA47111A - Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer - Google Patents

Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer

Info

Publication number
MA47111A
MA47111A MA047111A MA47111A MA47111A MA 47111 A MA47111 A MA 47111A MA 047111 A MA047111 A MA 047111A MA 47111 A MA47111 A MA 47111A MA 47111 A MA47111 A MA 47111A
Authority
MA
Morocco
Prior art keywords
sirpgamma
cancer
treatment
targeting agents
targeting
Prior art date
Application number
MA047111A
Other languages
English (en)
Inventor
xiu-wu Bian
Mark Furth
Molina Sarah Haigh
Hui-Kuan Lin
Chuan Xu
Original Assignee
Univ Wake Forest Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest Health Sciences filed Critical Univ Wake Forest Health Sciences
Publication of MA47111A publication Critical patent/MA47111A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
MA047111A 2016-12-22 2017-12-19 Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer MA47111A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662438227P 2016-12-22 2016-12-22

Publications (1)

Publication Number Publication Date
MA47111A true MA47111A (fr) 2019-10-30

Family

ID=61022415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047111A MA47111A (fr) 2016-12-22 2017-12-19 Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer

Country Status (4)

Country Link
US (1) US20230139592A1 (fr)
EP (1) EP3559037A1 (fr)
MA (1) MA47111A (fr)
WO (1) WO2018118887A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
MA53493A (fr) * 2018-08-31 2021-07-07 Alx Oncology Inc Polypeptides leurres
EP3986441A1 (fr) * 2019-06-24 2022-04-27 Amgen Inc. Inhibition de la sirp-gamma pour le traitement du cancer
WO2023086906A2 (fr) * 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Anticorps sirp gamma et leurs utilisations
CN114085869A (zh) * 2021-11-19 2022-02-25 许川 一种特异性表达人源性sirpg的转基因小鼠的构建方法及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510997A (en) 1893-12-19 Water-closet
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5103098A (en) 1989-11-09 1992-04-07 Board Of Regents, The University Of Texas System High resolution gamma ray detectors for positron emission tomography (pet) and single photon emission computed tomography (spect)
US5210421A (en) 1991-06-10 1993-05-11 Picker International, Inc. Simultaneous transmission and emission converging tomography
US5208581A (en) 1991-11-22 1993-05-04 General Electric Company High speed communication apparatus for computerized axial tomography (cat) scanners with matching receiver
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US5446799A (en) 1993-11-01 1995-08-29 Picker International, Inc. CT Scanner with improved processing efficiency 180 degrees+ fan angle reconstruction system
US5406479A (en) 1993-12-20 1995-04-11 Imatron, Inc. Method for rebinning and for correcting cone beam error in a fan beam computed tomographic scanner system
US5600145A (en) 1995-01-19 1997-02-04 Picker International, Inc. Emission/transmission device for use with a dual head nuclear medicine gamma camera with the transmission source located behind the emission collimator
US5608221A (en) 1995-06-09 1997-03-04 Adac Laboratories Multi-head nuclear medicine camera for dual SPECT and PET imaging with monuniform attenuation correction
SE9602594D0 (sv) 1996-07-01 1996-07-01 Stefan Nilsson Förfarande och anordning vid datortomografi
US5841140A (en) 1997-01-08 1998-11-24 Smv America, Inc. Gamma camera for pet and spect studies
US5946371A (en) 1997-12-08 1999-08-31 Analogic Corporation Method and apparatus for volumetric computed tomography scanning with offset symmetric or asymmetric detector system
US6115446A (en) 1999-04-09 2000-09-05 Arch Development Corp. Fast reconstruction of fan-beam CT and SPECT
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
WO2006110728A2 (fr) 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
WO2010037134A2 (fr) * 2008-09-29 2010-04-01 Stemlifeline, Inc. Carcinogenese de cellules souches multietapes
WO2012009568A2 (fr) 2010-07-16 2012-01-19 Adimab, Llc Banques d'anticorps
EP2593595B1 (fr) 2010-07-16 2020-03-11 Avantgen, Inc. Nouveaux peptides et leurs utilisations
WO2014100490A1 (fr) 2012-12-19 2014-06-26 Adimab, Llc Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
CA2939293C (fr) * 2014-03-11 2023-10-03 The Board Of Trustees Of The Leland Standford Junior University Anticorps anti-sirp-alpha et anticorps bispecifiques de stimulation des macrophages
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
AU2015329696A1 (en) * 2014-10-10 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
WO2016187226A1 (fr) * 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Compositions de polypeptide sirp et procédés d'utilisation
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells

Also Published As

Publication number Publication date
US20230139592A1 (en) 2023-05-04
WO2018118887A1 (fr) 2018-06-28
EP3559037A1 (fr) 2019-10-30

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA49144A (fr) Polythérapies pour le traitement du cancer
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
MA45563A (fr) Méthodes de traitement du cancer de l'ovaire
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
DK3107563T3 (da) Glycomålrettede terapeutiske midler
MA50409A (fr) Polythérapies pour le traitement du cancer
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA46361A (fr) Traitement du cancer de la prostate
MA47408A (fr) Traitement du cancer
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA46062A (fr) Traitement par ascaroside de l'oesophagite à éosinophiles